ATTRACT | What is ASA404? An Investigational Medication For Cancer Treatment
ATTRACT Clinical Trial Website - ATTRACT Logo
Search This Website:
Novartis Oncology Logo
U.S. Flag - Click If U.S. Resident for U.S. ATTRACT Clinical Trial Website Click here to email this page Click here to print this page
Antivascular Targeted Therapy Researching ASA404 in Cancer Treatment ATTRACT Clinical Trial Website Header – Blue Graphic ATTRACT Clinical Trial Website Header – Image of Couple
Home What is ASA404?

What is ASA404?

ASA404, a flavone-8-acetic acid analogue, is a novel Tumor-Vascular Disrupting Agent (Tumor-VDA). The tumor vasculature is a validated target for selective cancer therapy.1 Unlike antiangiogenic agents, which predominantly inhibit neovascularization, Tumor-VDAs target the established tumor vasculature for cancer treatment.2 Tumor-VDAs inhibit tumor blood flow, which deprives tumors of the necessary nutrients, leading to tumor necrosis.

ASA404 is a Tumor-VDA with a unique mechanism of action which comprises direct and indirect anti-tumor activity.3 Direct tumor endothelial cell apoptosis results in a rapid reduction in tumor blood flow and increased tumor vascular permeability. In the second stage, ASA404 induces the release of Tumor Necrosis Factor-α (TNF-α) and nitric oxide. This intratumoral vasoactive cascade results in a sustained collapse of tumor blood flow and extensive tumor necrosis. Synergistic activity of ASA404 and chemotherapy has been demonstrated in preclinical models.4,5 There is a clear rationale for combining ASA404 with standard chemotherapy.4,5 In a randomized Phase II study, ASA404, in combination with paclitaxel/carboplatin, was well tolerated and demonstrated a survival advantage in first-line treatment of advanced squamous and non-squamous Non-Small Cell Lung Cancer (NSCLC).6,7

ASA404 is currently being investigated in a phase III development program in first-line NSCLC. It is also being evaluated as cancer treatment in other solid tumors.

References
1. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10:415-427.
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423-435.
3. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003;4:141-148.
4. Kelland LR. Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev. 2005;1:1-9.
5. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol. 2003;51:43-52.
6. von Pawel J, Reck M, McKeage M, AS1404-201 Study Group Investigators. Update on survival in a phase Ib/II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Presented at AACR-NCI-EORTC. November 2006; Prague, Czech Republic.
7. M c Keage M, von Pawel J, ASA404-201 Study Group Investigators. Phase II study of DMXAA (ASA404) 1800mg/m2 combined with carboplatin and paclitaxel in non-small cell lung cancer. Presented at World Lung Cancer Conference. September 2007; Seoul, South Korea.